HER2阳性转移性结肠直肠癌
Hannah R Robinson1, Wells A Messersmith1, Robert W Lentz2
1Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, MS 8117, 12801 E. 17Th Avenue, Aurora, CO, 80045, USA.
Current treatment options in oncology
|March 28, 2024
概括
针对HER2的治疗方法为转移性结直肠癌 (mCRC) 提供了新的选择. 优选的是trastuzumab加上tucatinib,而其他药物如T-DXd则被认为是以后的治疗线.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 人类表皮生长因子受体2 (HER2) 阳性转移性结直肠癌 (mCRC) 有可用的向治疗策略.
- 对于被诊断患有mCRC的患者来说,HER2测试至关重要.
- 目前的一线治疗包括化学疗法与EGFR抑制剂或贝瓦齐祖马布结合,以RAS/BRAF状态和瘤侧向为指导.
研究的目的:
- 审查目前针对HER2阳性mCRC的向治疗策略.
- 讨论 HER2 向剂在不同治疗线和患者子组中的作用.
- 要突出不确定性和未来的方向在mCRC的HER2向治疗的领域.
主要方法:
- 审查现有临床证据和对HER2阳性mCRC的治疗指南.
- 对各种针对HER2的药物的疗效和毒性概况的分析.
- 讨论治疗序列,组合策略和生物标志物的利用.
主要成果:
- 特拉斯图祖马布加上图卡提尼布的组合是FDA批准的,通常是首选的.
- 其他药物,如trastuzumab加lapatinib,trastuzumab加pertuzumab和trastuzumabderuxtecan (T-DXd) 显示出有效性.
- 尽管有更高的毒性风险,但T-DXd在后一代中表现出活性,特别是在RAS突变的mCRC中.
结论:
- 针对HER2的药物在mCRC中很有价值,特别是在RAS/BRAF野生型疾病中.
- 对HER2疗法的最佳测序和组合伙伴需要进一步研究.
- 正在进行的研究和生物标志物开发预计将在mCRC中完善HER2向治疗范式.
关键词:
结肠直肠癌是一种癌症.在ERBB2中,它是ERBB2.在HER2中,HER2是HER2.皮尔图祖马布 (Pertuzumab) 是一种药物.这就是Trastuzumab.图卡替尼布 (Tucatinib) 是一种更多相关视频
11:12Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.0K
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
114
相关概念视频
02:30Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K